From 1 November 1992 through 1 May 1993 and from 1 November 1993 through 1 May 1994, we conducted a prospective surveillance study at the University of Texas M.D. Anderson Cancer Center (Houston) to evaluate the role of community respiratory virus infections in hospitalized adult bone marrow transplant (BMT)recipients. Respiratory secretions were obtained from all adult BMT recipients with acute respiratory illnesses.During these two winters, a community respiratory virus was isolated from 37 (36%)of 102patients and 30 (26%)of 115patients, respectively. Approximately half (49%) of these infections were due to respiratory syncytial virus (RSV); the remainder were due to influenza virus (18%), picornaviruses (18%), parainfluenza virus (9%), or adenovirus (6%). Fifty-eight percent of these infections were complicated by pneumonia, with an associated mortality of 51%. The pneumonias that complicated RSV infection were almost exclusively viral in origin and were associated with a mortality of 100%if not treated promptly with antiviral agents. In contrast, many of the pneumonias that complicated the other viral infections, such as influenza, appeared to be either self-limited viral pneumonias or secondary bacterial or fungal pneumonias. Community respiratory viruses are frequent causes of acute respiratory illnesses in adult BMT recipients hospitalized during the winter and are associated with substantial morbidity and mortality.
Pneumonia is one of the most common infectious complications of bone marrow transplantation, and it is frequently fatal. Until recently, the majority of viral pneumonias occurring in bone marrow transplant (BMT) recipients were attributed to the herpesviruses (predominantly cytomegalovirus) [I) . However, evidence has been accumulating that community respiratory viruses such as respiratory syncytial virus (RSV), influenza virus, parainfluenza virus, adenovirus, and picornaviruses also play an important role in the etiology of respiratory diseases in BMT recipients and that infection with these viruses may explain many of the pneumonias previously classified as idiopathic [1). To assess the relative importance of these viruses in disease of the upper and lower respiratory tracts, we prospectively followed up all adult BMT recipients hospitalized at the University of Texas M. D. Anderson Cancer Center (MDACC; Houston) who developed acute respiratory illnesses during two consecutive winter seasons.
Methods
Patients. Respiratory secretions were obtained from 1 November 1992 through 1 May 1993 and from 1 November 1993 through 1 May 1994 from all adult BMT recipients with acute respiratory illnesses who were hospitalized at MDACC. Samples were submitted for viral culture and rapid RSV-antigen testing by means of ELISA and/or indirect immunofluorescence. Only cases confirmed by culture were analyzed. Samples were not obtained from asymptomatic patients.
Definitions. An acute upper respiratory tract illness was defined as the presence of rhinorrhea, nasal congestion or sinus congestion, otitis media, pharyngitis, and/or cough, with a clear chest radiograph. Pneumonia was defined as an acute respiratory illness occurring in association with a new radiographic infiltrate.
Infections were considered to be hospital acquired if symptoms developed~7 days after admission. Neutropenia was
Results
During the first winter (1992-1993), community respiratory viruses were isolated from 36% of the adult BMT recipients NOTE. There were a total of 102 and 115 acute respiratory illnesses during 1992-1993 and 1993-1994 , respectively.
* From 1 November through 1 May. hospitalized with acute respiratory illnesses, and during the second winter (1993) (1994) , these viruses were isolated from 26% of such patients (table I) . Approximately half (49%) of these infections were due to RSV; the remainder were due to influenza virus (\8%), picornaviruses (\8%), parainfluenza virus (9%), and adenovirus (6%). The various infections were interspersed throughout these periods (figure 1).
The clinical characteristics and clinical courses of the 67 patients with community respiratory virus infections are detailed in tables 2 and 3. The infections occurred with similar frequency among recipients of both autologous and allogeneic transplants. More than half of the infections associated with RSV, influenza, adenovirus, and picomaviruses were complicated by either primary viral pneumonia or secondary bacterial pneumonia.
RSV RSV was isolated from 33 patients, all of whom initially presented with upper respiratory tract illnesses characterized by rhinorrhea, nasal congestion and sinus congestion, sore throat, and cough. The infection progressed to pneumonia in 20 patients (61%). The risk of pneumonia was closely related to the interval between transplantation and the appearance of symptoms. Sixteen (76%) of 21 patients developed pneumonia < 1 month after transplantation. In contrast, only 2 (22%) of 9 patients developed pneumonia >6 months after transplantation (P < .05). These two patients had relapse of leukemia and profound chemotherapy-induced myelosuppression.
Sixteen patients with RSV pneumonia were treated with a combination of aerosolized ribavirin (20 mg/mL for 18 hours per day) and intravenous immunoglobulin (500 mg/kg every other day) for a mean of 12 days (range, I -22 days). With use of a standardized microneutralization assay for RSV subtypes A and B [4] , selected lots of intravenous immunoglobulin were chosen that contained RSV microneutralization titers ranging from I:2,048 to 1: 8, 196 in 5% solution. The length of therapy was individualized on the basis of the severity of illness, clinical response, and engraftment status.
Early initiation of therapy was associated with a favorable outcome. Four of 12 patients in whom Iherapy was initiated> 1 day before the onset of respiratory failure requiring mechanical ventilation died. In contrast, all four patients in whom therapy was initiated within 1 day of intubation died, as did all four untreated patients (P < .05).
Seven of the 12 patients with fatal RSV pneumonia were autopsied. Histopathological examination of lung tissue samples from all seven patients revealed multinucleated syncytial cells or giant cells with intracytoplasmic viral inclusions, consistent with RSV pneumonia. Immunohistochemical studies with monoclonal antibodies (858-4; Chemicon International, Temecula, CAl confirmed the diagnosis. Only one patient had a concurrent infection (disseminated candidiasis).
Influenza virus. Influenza virus was isolated from 12 patients (type A was isolated from nine and type B from three). Almost all (11) [2] , and parainfluenza viruses were identified and typed with use of type-specific fluorescein-conjugated antibody (Bartels Immunodiagnostic Supplies). Picornaviruses were identified following the appearance of a characteristic cytopathic effect, as detected with use of PCR [3] . Adenovirus was identified by using a polyclonal fluorescein-conjugated antibody (Bartels lmmunodiagnostic Supplies).
Statistical analysis. Differences between categorical variables were tested for significance with use of the two-tailed Fisher's exact test. tract illness, as did the RSV infections, and eight of these infections were complicated by pneumonia. Unlike the RSV pneumonias, however, at least half of these influenza-associated pneumonias appeared to be secondary bacterial or fungal pneumonias rather than primary viral pneumonias, as judged by their response to antibacterial therapy (three patients) or by findings at autopsy (one patient with fusarium pneumonia). Four of the eight patients with pneumonia survived; no other pulmonary pathogens were identified. Three of these patients were treated with broad-spectrum antibiotics, but not with antiviral medications, suggesting that they had either self-limited viral pneumonias or secondary bacterial pneumonias. The other patient who survived was treated with rimantadine, aerosolized ribavirin, and broad-spectrum antibiotics.
Four patients died of progressive pneumonia. These patients all received broad-spectrum antibiotics, but no antiviral therapy. Autopsy revealed invasive influenza virus pneumonia in two patients in whom no other pathogens were identified and fusarium pneumonia in a third patient. One of the two patients with lymphoma and documented fatal influenza-associated pneumonia developed severe myelosuppression early «30 days) after undergoing autologous BMT; the other patient was receiving immunosuppressive therapy for chronic graft-versushost disease 9 months after undergoing allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Picornavirus. Picomaviruses were isolated from 12 patients, 11 of whom initially presented with upper respiratory tract illnesses. These illnesses were complicated by pneumonia in seven of the patients. The etiologies of these pneumonias were not clearly defined, although no other pulmonary pathogens were identified. All seven patients were treated with broad-spectrum antibiotics. Two of these seven patients, both of whom survived, were also treated with aerosolized ribavirin. Three patients, all of whom had clinical and radiographic courses consistent with progressive viral pneumonia, died. Autopsies of two of these patients revealed diffuse nonspecific lung damage, consistent with, but not diagnostic of, viral pneumonia.
Parainfluenzavirus. Parainfluenza virus was isolated from
six patients, five of whom developed severe myelosuppression < 30 days after transplantation. All of these patients presented with upper respiratory tract illnesses, but only one developed pneumonia. None of the patients received antiviral therapy. In contrast to the high number of deaths associated with RSV infections that developed during the early posttransplantation period, there were no deaths in this group.
Adenovirus. Adenovirus was isolated from four patients.
In contrast to the typical clinical presentations of patients infected with the other viruses, three of these four patients presented with pneumonias that were not preceded by upper respiratory tract illnesses. All four patients were treated with broadspectrum antibiotics, but none received antiviral therapy. One patient died; this patient had cytomegalovirus, Pneumocystis carinii, and adenovirus isolated from bronchoalveolar lavage fluid. Because an autopsy was not performed, the contribution of adenovirus infection to the development ofpneumonia could not be evaluated.
Discussion
Pneumonias occurring in adult BMT recipients are traditionally attributed to bacteria, fungi, P. carinii, and herpesviruses Table2. Characteristics of 67 hospitalized adultbonemarrow transplant recipients with a community respiratory virus infection.
NOTE. The study was conducted from 1 November 1992 through I May 1993 and from 1 November 1993 through I May 1994.
• The mean age of these patients was 38.6 years (range 19-59 years). t Engraftment was defined as the resolution of neutropenia after bone marrow transplantation.
[1]. Until recently, minimal attention has been paid to the role of community respiratory viruses [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . This is due in part to the fact that the potentially fatal consequences of seemingly trivial viral upper respiratory tract illnesses in these immunocompromised patients have not been adequately recognized.
The results of our study suggest that community respiratory viruses are important causes ofpotentially serious acute respira- tory illnesses in hospitalized adult BMT recipients. During two consecutive 6-month winter seasons, approximately one-third of such patients at MDACC were infected with one of these viruses. In contrast to the classic tenet that one respiratory virus predominates at anyone time in a community, multiple viruses were isolated continuously during these winter study periods. Although RSV predominated during the 1992-1993 season, a precise prediction of disease, based on epidemiology or even on the prevalence of viruses in the community, was difficult. The morbidity and mortality associated with these infections were substantial. More than half (58%) of these infections were complicated by pneumonia, with an associated mortality of 51%. In patients with RSV infection, the pneumonias were almost exclusively viral in origin and were associated with a mortality of 100% if not treated promptly with aerosolized ribavirin. Many of the pneumonias in patients infected with the other viruses, such as influenza virus, appeared to be either self-limited viral pneumonias or appeared to have a substantial bacterial component, as judged by their favorable response to antibacterial therapy. However, fatal viral pneumonias occurred as well. It is noteworthy that only a few infections due to parainfluenza virus and adenovirus were observed during these winter seasons and that their potential to cause fatal viral pneumonia was not appreciated [5, 13, 14, 16, 17] .
In evaluating a BMT recipient with an acute respiratory illness, community respiratory viruses must be considered seriously and promptly, especially if the patient has signs and symptoms of an upper respiratory tract illness. Consideration of these pathogens is particularly important because viral pneumonias, such as those associated with RSV, need to be treated aggressively with antiviral drugs at an early stage in order to avoid a fatal outcome. Moreover, these contagious infections may cause nosocomial outbreaks. Their transmission must be prevented by rigorous hospital infection control measures, including institution of strict respiratory and contact precautions and restriction of visitors and hospital personnel who have respiratory illnesses. Because ofthe high morbidity and mortal- ity associated with these infections during the early posttransplantation period, potential BMT recipients should be rigorously screened for minimal signs and symptoms of acute respiratory illnesses; if evidence ofsuch illness is present, evaluation of nasopharnygeal washes by means of viral cultures should be undertaken. Transplantation should be delayed, if feasible, until the illness has resolved, particularly if it is due to RSV.
In summary, community respiratory viruses are important causes of acute upper respiratory tract illnesses, as well as lower respiratory tract illnesses, among hospitalized adult BMT recipients. The risk factors for progression of upper respiratory tract illnesses to pneumonias that are severe and often fatal in these patients, as well as other severely immunocompromised patients, need to be better defined [20, 21] so that appropriate preventive and therapeutic measures can be instituted.
